Tenax Therapeutics (TENX) Stock Price, Quote & News

Company Profile

Tenax Therapeutics, Inc., a development-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States. It develops TNX-101, TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension in heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was for...

Industry: Biotechnology

Sector: Healthcare

Phone: 919 855 2100

Website: www.tenaxthera.com

Address:

101 Glen Lennox Drive, Suite 300, Chapel Hill, United States

Narutoosaka May. 11 at 11:51 PM

$TENX $TENX Extremely bullish setup developing here. TNX-103 isn’t some brand-new untested molecule — levosimendan already has years of international clinical experience and physician familiarity. That dramatically lowers the scientific risk compared to many early-stage biotech names. The company just completed enrollment in the Phase 3 LEVEL trial ahead of topline data expected in Q3 2026, which is a massive milestone. Institutions clearly recognize the opportunity here — major biotech funds like RTW, BVF, Janus, Vivo, Venrock and T. Rowe Price are involved. Most importantly, TENX is targeting PH-HFpEF, a huge unmet medical need with very limited treatment options. If TNX-103 shows strong efficacy, this could become one of the most important cardiopulmonary therapies in the space. The market is finally starting to understand: * Existing international experience with levosimendan * Strong KOL support * Fully enrolled Phase 3 program * Institutional accumulation * Large addressable

0 · Reply

Machiaveltrade May. 11 at 9:01 PM

$TENX

0 · Reply

BanditQ May. 11 at 8:24 PM

$TENX

0 · Reply

jangy1 May. 11 at 7:07 PM

$TENX

0 · Reply

betonthenews May. 11 at 6:24 PM

$TENX Ask GOOGL AI about bullish comments of OLE patients in LEVEL tria: https://www.google.com/search?q=When+trial+Drs+are+commenting+that+OLE+trial+patients+are+unblinded%2C+do+Drs+know+which+patients+is+the+placebo+arm+when+he%2Fshe+goes+into+OLE%3F&sca_esv=43a6c5a008a39361&sxsrf=ANbL-n4QHYkPSluWeqS9PpgaSQuvk0eSaQ%3A1778522844001&ei=2xoCatKgOrf3kPIPs6GQgAg&iflsig=AFdpzrgAAAAAagIo7F_ny7lfZa9hzrEx6srYt-grvXFM&uact=5&sclient=gws-wiz&udm=50&fbs=ADc_l-aN0CWEZBOHjofHoaMMDiKpaEWjvZ2Py1XXV8d8KvlI3u6MWRtAr31GIrXLfiKhJJ8rW39M0T_N8wn3kINg3nQk-dwTV6GiRqsz_UCAHf8NRRm3-bLpKF0igO6vIxoD7dU3PKEd9jFcuDBYJPGxWUMhvD0VywwX_wfL28AMwmoJb2XoDKFAo2blKqqNwgyaECNl61KuxI3ZkcjHZSKocIyV74D3tw&aep=10&ntc=1&mstk=AUtExfCkfb20FwcVcFI8SdTyGofPx30hQ_pTDCQJ4FvHdxXwXZfs0f0qLs-FNGcz6d0QpDTXdR4fM-Ul19c7392Z0wDwYR0WQKayY6MvQ2wuKVFacrrSOf5Iqxov7MXcs4sE91UpBpi33k3CJONEuQ5T5jddghV6m4_Lv1yNIaq3lfxZXs0hVzWFtJZD-toqJlhOQEfDwCZzATdKgesznDido7bvEt5HZ7j3sh0y-DZJU5LqoLHYDrWc5bvsTby8o85mTqkCdx1zIBmfF7b7tUUkQEfq3fPcbGbW4wm9SV5Stru6UrdoVSn6ytKdnhD3eFgcWgPm6TpRbvt5UA&aioh=3&csuir=1&cs=0&mtid=XBwCarHWHY3VkPIP6O_ZkA4

0 · Reply

betonthenews May. 11 at 6:21 PM

$TENX Continue from last post: (like the 6-minute walk distance) or symptom relief compared to their baseline performance during the first 12 weeks, doctors can often identify which patients were previously on placebo.Anecdotal Observations in Ongoing Trials: Even while the overall LEVEL trial is "ongoing" (not yet reaching its final 2H 2026 topline readout), over 95% of patients who finish the 12-week phase have historically elected to enter the OLE. This creates a pool of "unblinded" data that KOLs (Key Opinion Leaders) can discuss based on real-world clinical observation.Blinded Sample Size Re-estimation (BSSR): In December 2025, Tenax released data from a Blinded Sample Size Re-estimation (BSSR). While the aggregate data for that specific assessment remained blinded to maintain trial integrity, the individual patient experiences in the OLE provided the "positive anecdotes" discussed by doctors in the November call.

0 · Reply

betonthenews May. 11 at 6:20 PM

$TENX FWIW: In the context of the Tenax Therapeutics (TENX) KOL Discussion on November 13, 2025, doctors were able to comment on "unblinded" patient outcomes because they were referencing anecdotal data from the Open-Label Extension (OLE) of the Phase 3 LEVEL study and previous Phase 2 trials.Do Doctors Know the Placebo Arm in OLE?In the Tenax LEVEL trial case, investigators specifically know who was in the placebo arm for the following reasons:Completion of the 12-Week Blinded Phase: In the LEVEL study, the randomized, double-blind portion lasts only 12 weeks. Once a patient completes these 12 weeks, they transition to the OLE where the "blind" for that specific patient is broken to allow for active treatment.Knowledge of Treatment Transition: When a patient enters the OLE, the doctor is aware they are now receiving the active drug (TNX-103). Patients were previously on placebo.By reviewing the patient's sudden change in exercise capacity

0 · Reply

JFais May. 8 at 9:56 PM

Chat topics to finish the week: $AKBA- Auryxia sales down, but MC only 3x 2026 revenues if Vafseo gets to $100M annualized $TMDX EV/sales of ~4x. Buying opp or value trap? $TENX - appropriate sizing for this @A_May_MD lottery pick? 10x on clean win, zero if fails (true binary)

0 · Reply

BanditQ May. 8 at 6:06 PM

$TENX

1 · Reply

BanditQ May. 8 at 6:06 PM

$TENX LETS FKN GOOO

0 · Reply

Tenax Therapeutics reports Q1 EPS (35c), consensus (40c)

May 12, 2026, 7:00 AM EDT - 1 day ago

Tenax Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 8, 2026, 4:05 PM EDT - 4 days ago

Tenax Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2026-05-04T11:30:35.000Z - 9 days ago

Tenax Therapeutics appoints Timothy Healey as chief commercial officer

May 4, 2026, 7:00 AM EDT - 9 days ago

Tenax Therapeutics Appoints Timothy Healey, MBA as Chief Commercial Officer

Apr 22, 2026, 7:00 AM EDT - 21 days ago

Tenax Therapeutics Appoints Thomas R. Staab, II as Chief Financial Officer

2026-03-25T12:38:06.000Z - 6 weeks ago

Four new option listings on March 25th

IPX SUNC

2026-03-24T15:45:42.000Z - 7 weeks ago

Tenax Therapeutics files $300M mixed securities shelf

2026-03-17T11:31:28.000Z - 2 months ago

Cantor starts Tenax at Overweight into Phase 3 readout

2026-03-17T10:10:48.000Z - 2 months ago

Tenax Therapeutics initiated with an Overweight at Cantor Fitzgerald

2026-03-16T10:57:02.000Z - 2 months ago

Tenax Therapeutics price target raised to $34 from $25 at Guggenheim

2026-03-12T11:10:56.000Z - 2 months ago

Tenax Therapeutics initiated with an Outperform at LifeSci Capital

Mar 10, 2026, 2:20 PM EDT - 2 months ago

Tenax Therapeutics Transcript: Leerink Global Healthcare Conference 2026

2026-03-10T11:07:42.000Z - 2 months ago

Tenax Therapeutics reports Q4 EPS (38c), consensus (41c)

Mar 10, 2026, 7:00 AM EDT - 2 months ago

Tenax Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Mar 3, 2026, 7:00 AM EST - 2 months ago

Tenax Therapeutics to Participate in the 2026 Leerink Partners Global Healthcare Conference

Feb 11, 2026, 12:30 PM EST - 3 months ago

Tenax Therapeutics Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Feb 4, 2026, 7:00 AM EST - 3 months ago

Tenax Therapeutics to Participate in the Guggenheim Emerging Outlook Biotech Summit 2026

2025-12-17T14:26:01.000Z - 5 months ago

Tenax Therapeutics reports result of prespecified blinded sample size assessment

Dec 17, 2025, 9:16 AM EST - 5 months ago

Tenax Therapeutics Announces Result of Prespecifed Blinded Sample Size Assessment

2025-12-17T11:56:25.000Z - 5 months ago

Tenax Therapeutics price target raised to $25 from $14 at Guggenheim

Dec 4, 2025, 11:30 AM EST - 5 months ago

Tenax Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference

Dec 2, 2025, 4:15 PM EST - 5 months ago

Tenax Therapeutics Transcript: Evercore ISI 8th Annual HealthCONx Conference

Nov 25, 2025, 7:00 AM EST - 6 months ago

Tenax Therapeutics to Participate in Upcoming Investor Conferences

Nov 13, 2025, 4:30 PM EST - 6 months ago

Tenax Therapeutics Transcript: KOL Event

2025-11-13T15:55:21.000Z - 6 months ago

Tenax Therapeutics to hold a conference call

2025-11-12T22:20:13.000Z - 6 months ago

Tenax Therapeutics reports Q3 EPS (40c), consensus ($1.12)

Nov 12, 2025, 4:05 PM EST - 6 months ago

Tenax Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 10, 2025, 4:00 PM EST - 6 months ago

Tenax Therapeutics Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 6, 2025, 7:00 AM EST - 6 months ago

Tenax Therapeutics to Host Virtual KOL Call to Discuss TNX-103 (Oral Levosimendan) for the Treatment of PH-HFpEF

Nov 3, 2025, 7:00 AM EST - 6 months ago

Tenax Therapeutics to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference

2025-10-01T20:25:07.000Z - 7 months ago

Tenax Therapeutics management to meet with Piper Sandler

2025-09-16T11:11:02.000Z - 8 months ago

Tenax announces EPO intention to grant patent for levosimendan in PH-HFpEF

Sep 16, 2025, 7:00 AM EDT - 8 months ago

Tenax Therapeutics Announces European Patent Office Intention to Grant Patent Covering Use of Levosimendan in PH-HFpEF

2025-09-08T08:55:10.000Z - 8 months ago

Tenax Therapeutics initiated with an Overweight at Piper Sandler

Sep 4, 2025, 10:20 AM EDT - 8 months ago

Tenax Therapeutics Transcript: Cantor Global Healthcare Conference 2025

Aug 28, 2025, 7:00 AM EDT - 9 months ago

Tenax Therapeutics to Participate in the Cantor Global Healthcare Conference 2025

2025-08-13T20:21:39.000Z - 9 months ago

Tenax Therapeutics reports Q2 EPS (27c), consensus (45c)

Aug 13, 2025, 4:05 PM EDT - 9 months ago

Tenax Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

2025-06-20T17:45:18.000Z - 11 months ago

Tenax Therapeutics trading resumes

2025-06-20T17:40:09.000Z - 11 months ago

Tenax Therapeutics trading halted, volatility trading pause

May 14, 2025, 4:05 PM EDT - 1 year ago

Tenax Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Apr 7, 2025, 3:45 PM EDT - 1 year ago

Tenax Therapeutics Transcript: 24th Annual Needham Virtual Healthcare Conference

Mar 31, 2025, 8:00 AM EDT - 1 year ago

Tenax Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

Mar 25, 2025, 4:05 PM EDT - 1 year ago

Tenax Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Mar 10, 2025, 3:40 PM EDT - 1 year ago

Tenax Therapeutics Transcript: Leerink’s Global Healthcare Conference 2025

Mar 5, 2025, 8:47 AM EST - 1 year ago

Tenax Therapeutics Announces $25 Million Private Placement

Mar 5, 2025, 8:42 AM EST - 1 year ago

Tenax Therapeutics Expands Phase 3 LEVEL Program, Advancing Two TNX-103 (Oral Levosimendan) Registrational Studies for the Treatment of PH-HFpEF

Mar 3, 2025, 8:00 AM EST - 1 year ago

Tenax Therapeutics to Participate in the Leerink Partners 2025 Global Healthcare Conference

Feb 5, 2025, 3:00 PM EST - 1 year ago

Tenax Therapeutics Transcript: Guggenheim SMID Cap Biotech Conference

Jan 31, 2025, 9:00 AM EST - 1 year ago

Tenax Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference

Nov 13, 2024, 7:00 AM EST - 1 year ago

Tenax Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update

Oct 31, 2024, 4:05 PM EDT - 1 year ago

Tenax Therapeutics to Present at the Guggenheim Healthcare Innovation Conference

Aug 6, 2024, 7:13 AM EDT - 1 year ago

Tenax Therapeutics Announces Oversubscribed $100 Million Private Placement

May 14, 2024, 8:00 AM EDT - 2 years ago

Tenax Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update

Apr 30, 2024, 7:30 AM EDT - 2 years ago

Tenax Therapeutics Announces New U.S. Patent Covering the Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

Apr 9, 2024, 8:30 AM EDT - 2 years ago

Tenax Therapeutics to Host KOL Event: “LEVEL Setting: the Scientific Rationale for Levosimendan as a Potential First Treatment for PH-HFpEF, and the Ongoing Phase 3 LEVEL Study”

Mar 28, 2024, 8:30 AM EDT - 2 years ago

Tenax Therapeutics Provides Business and Clinical Development Updates with Full Year 2023 Financial Results

Mar 12, 2024, 8:30 AM EDT - 2 years ago

Tenax Therapeutics to Present at the 36th Annual Roth Conference

Feb 29, 2024, 9:00 AM EST - 2 years ago

Tenax Therapeutics Announces Oral Presentation of Levosimendan for the Treatment of PH-HFpEF at THT 2024

Feb 20, 2024, 8:30 AM EST - 2 years ago

Tenax Therapeutics Announces Global License Amendment that Significantly Expands Rights to Levosimendan

Feb 8, 2024, 8:16 AM EST - 2 years ago

Tenax Therapeutics Announces Pricing of Approximately $9 Million Public Offering

Feb 7, 2024, 8:01 PM EST - 2 years ago

Tenax Therapeutics Enrolls First Patient in Phase 3 LEVEL Study Evaluating TNX-103 (Oral Levosimendan) for the Treatment of Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

Feb 6, 2024, 10:01 AM EST - 2 years ago

Biotech stock Tenax Therapeutics more than doubled on Tuesday

Feb 6, 2024, 8:30 AM EST - 2 years ago

Tenax Therapeutics Announces USPTO Grants Notice of Allowance for U.S. Patent Application, Significantly Broadening IP Protection for Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

Dec 29, 2023, 8:30 AM EST - 2 years ago

Tenax Therapeutics Announces Reverse Stock Split

Nov 17, 2023, 8:30 AM EST - 2 years ago

Tenax Therapeutics Announces Professor Javed Butler, M.D., M.P.H, M.B.A.

Nov 13, 2023, 8:30 AM EST - 2 years ago

Tenax Therapeutics Announces FDA Clearance of IND for TNX-103 (oral levosimendan) for the Treatment of Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF), Initiation of Phase 3 sites expected 2023

Jul 19, 2023, 8:30 AM EDT - 3 years ago

Tenax Therapeutics Issued U.S. Patent for Oral Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

May 31, 2023, 8:54 AM EDT - 3 years ago

Tenax Therapeutics Achieves Major Milestone as USPTO Grants Notice of Allowance for U.S. Patent Application Covering Use of Oral Levosimendan (TNX-103) in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

Apr 12, 2023, 8:45 AM EDT - 3 years ago

Tenax Therapeutics Provides 2023 Business Update

Mar 22, 2023, 8:45 AM EDT - 3 years ago

Tenax Announces Issuance of U.S. Patent Covering Use of IV Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

Feb 3, 2023, 8:19 AM EST - 3 years ago

Tenax Therapeutics Announces Pricing of Approximately $15.6 Million Public Offering

Feb 1, 2023, 4:31 PM EST - 3 years ago

Tenax Granted Notice of Allowance for U.S. Patent Application Covering Use of IV Levosimendan in Pulmonary Hypertension with Heart Failure and Preserved Ejection Fraction (PH-HFpEF)

Oct 10, 2022, 8:30 AM EDT - 3 years ago

Positive Data Presented at HFSA Annual Meeting Demonstrate Effects of Oral Levosimendan in Patients with Pulmonary Hypertension and Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

Sep 15, 2022, 8:30 AM EDT - 3 years ago

Tenax Therapeutics Announces the Evaluation of Strategic Alternatives

May 23, 2022, 8:30 AM EDT - 4 years ago

Tenax Therapeutics Announces Successful Comparative Pharmacokinetic Study of TNX-201 for the Treatment of Pulmonary Arterial Hypertension

May 18, 2022, 8:30 AM EDT - 4 years ago

Tenax Therapeutics Announces $8 Million PIPE Offering Priced At-the-Market under Nasdaq Rules

Mar 31, 2022, 8:30 AM EDT - 4 years ago

Tenax Therapeutics Reports Fiscal Year 2021 Results and Provides Business Update

Narutoosaka May. 11 at 11:51 PM

0 · Reply

Machiaveltrade May. 11 at 9:01 PM

$TENX

0 · Reply

BanditQ May. 11 at 8:24 PM

$TENX

0 · Reply

jangy1 May. 11 at 7:07 PM

$TENX

0 · Reply

betonthenews May. 11 at 6:24 PM

0 · Reply

betonthenews May. 11 at 6:21 PM

0 · Reply

betonthenews May. 11 at 6:20 PM

0 · Reply

JFais May. 8 at 9:56 PM

0 · Reply

BanditQ May. 8 at 6:06 PM

$TENX

1 · Reply

BanditQ May. 8 at 6:06 PM

$TENX LETS FKN GOOO

0 · Reply

BanditQ May. 8 at 3:52 PM

$TENX sold a big chunk of $EQ and went all in $TENX with it. We'll see what happens IDGAFFF

0 · Reply

Cr0upier May. 7 at 5:25 PM

$TENX Tiiiiiiiimmmmmmmmmbbbbbbbbeeeeeeerrrrrrr!!!!!! Still going to $100.

0 · Reply

betonthenews May. 7 at 4:16 PM

$TENX Hard lessons learned from GOSS: very weak and mixed small PII data, strong enrollment P3 and very high 85-90% patients continuing into open label extension trial, very bullish CEO and KOL opinions, but P3 topline data failed and not event close for P 0.05. Watch $TENX and $SLS now, very similar to GOSS conditions going into P3 topline data, hard to call the outcomes for both of them, IMO.

2 · Reply

Machiaveltrade May. 7 at 9:56 AM

$TENX let’s see next shoulder soon

0 · Reply

Machiaveltrade May. 6 at 8:06 PM

$TENX add a lot today😁

0 · Reply

SuperGreenToday May. 5 at 10:35 PM

$TENX Share Price: $12.53 Contract Selected: Aug 21, 2026 $15 Calls Buy Zone: $3.82 – $4.73 Target Zone: $6.54 – $8.00 Potential Upside: 62% ROI Time to Expiration: 107 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

squiggleburp May. 5 at 7:32 PM

$TENX What’s happening here? The price finally got to where I was hoping to enter but now I fear we leg down a bit more. Watching with my good eye, the other one wanders so it’s really hard to focus on anything.

0 · Reply

Cr0upier May. 5 at 7:11 PM

$TENX I'm buying more.

1 · Reply

Mimarcano May. 1 at 4:09 PM

$TENX earnings 5/16 💪💪

0 · Reply

JoshNz May. 1 at 2:32 PM

$TENX I am still bullish, Hoping it goes down even lower so I can buy more.

0 · Reply

PeelonDusk May. 1 at 6:38 AM

$TENX can I get 12.50 😁

0 · Reply

biospeculator Apr. 29 at 9:42 PM

$TENX In Nov. 2025 only 6 months ago I bought shares at $6+. At the time the shares available were 7M for a market cap of $43M. Six months later without any news releases we find 25M shares and a market cap of $325M. In addition, the institutional ownership went from 120% to today's number per NASDAQ of 31% due to this unprecedented dilution. My target at the time was 500M if the phase III is successful. It is with pleasure I sold this and now will remove it from my screen. This is biotech and Wall Street imo at its worst. Management should imo be barred from running a public company.

1 · Reply

Market Cap	205.52M
Revenue (ttm)	0.00
Net Income (ttm)	-52.60M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	511,800
Avg Vol	563,608
Day's Range	N/A - N/A
Shares Out	17.20M
Stochastic %K	33%
Beta	1.00
Analysts	Strong Sell
Price Target	$28.67